Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by West Paces Advisors Inc.

West Paces Advisors Inc. grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 575.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 27 shares of the biopharmaceutical company’s stock after purchasing an additional 23 shares during the period. West Paces Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $26,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 8,838,285 shares of the biopharmaceutical company’s stock worth $7,762,577,000 after acquiring an additional 39,780 shares in the last quarter. Capital World Investors boosted its stake in shares of Regeneron Pharmaceuticals by 0.5% during the 4th quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock worth $4,506,071,000 after acquiring an additional 23,146 shares in the last quarter. Putnam Investments LLC lifted its stake in Regeneron Pharmaceuticals by 2.1% in the 4th quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock valued at $1,063,377,000 after buying an additional 24,329 shares in the last quarter. Norges Bank purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $932,571,000. Finally, Morgan Stanley lifted its stake in Regeneron Pharmaceuticals by 2.7% in the 3rd quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company’s stock valued at $799,061,000 after buying an additional 25,792 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Bank of America upped their target price on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. Evercore ISI assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 target price on the stock. Sanford C. Bernstein assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price on the stock. UBS Group increased their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Finally, StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 30th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,008.96.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $1,011.00, for a total value of $836,097.00. Following the sale, the director now owns 1,382 shares in the company, valued at $1,397,202. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $1,011.00, for a total transaction of $836,097.00. Following the transaction, the director now owns 1,382 shares in the company, valued at $1,397,202. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Leonard S. Schleifer sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the transaction, the chief executive officer now owns 408,200 shares in the company, valued at approximately $399,729,850. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 61,971 shares of company stock worth $61,217,654. 7.48% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded up $7.30 during trading hours on Tuesday, reaching $1,071.19. The company’s stock had a trading volume of 521,638 shares, compared to its average volume of 477,327. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The business has a 50-day simple moving average of $974.69 and a 200 day simple moving average of $947.43. Regeneron Pharmaceuticals, Inc. has a 52 week low of $684.80 and a 52 week high of $1,081.17. The stock has a market cap of $118.03 billion, a PE ratio of 31.65, a PEG ratio of 2.18 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The firm had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.12 earnings per share for the current fiscal year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.